Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma (BMUMM)
Primary Purpose
Cutaneous Melanoma
Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Ultrasound Biomicroscopy
Sponsored by
About this trial
This is an interventional diagnostic trial for Cutaneous Melanoma
Eligibility Criteria
Inclusion Criteria:
- Clinical suspicion of cutaneous melanoma
- Age ≥ 18 years
- Social Security affiliation
- Approval of patient and signature of informed consent form
Exclusion Criteria:
- Counter-indication to the surgical resection of the cutaneous melanoma
- Vulnerable patient (Under-supervision patients or deprived of liberty patients)
Sites / Locations
- CHU de NiceRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Experimental
Arm Description
Measure of cutaneous melanomas by ultrasound biomicroscopy
Outcomes
Primary Outcome Measures
Measurement of the Breslow Index with Ultrasound Biomicroscopy
The measurement of the thickness of the malignant melanoma will be carried out in Ultrasound Biomicroscopy in two orthogonal planes using the maximum value obtainedThe measurement will be performed pre-operatively with the device (transducer) attached to an articulated arm from the anterior edge of the lesion to the interface between the posterior border of the lesion and the underlying dermis or hypodermis.
The measurement will be expressed in mm. The histological measurement will be performed according to the usual techniques after fixation of the surgical specimen. It will also be expressed in µm.
Secondary Outcome Measures
Measurement of the thickness of the malignant melanoma with High Frequency Ultrasound (18MHz) and compare it to the result obtained by Ultrasound Biomicroscopy
Conventional High Frequency Ultrasound (18MHz) will be performed prior to Ultrasound Biomicroscopy analysis using an 18 MHz probe according to the usual technique used in High Frequency Ultrasound (freehand) and the thickness of the malignant melanoma will be expressed in µm. Standard gold is defined as at the main objective.
Measurement of the thickness of the malignant melanoma with High Frequency Ultrasound and compare it to the result obtained by Ultrasound Biomicroscopy
High Frequency Ultrasound (33MHz) will be performed prior to Ultrasound Biomicroscopy analysis using an 33 MHz probe according to the usual technique used in High Frequency Ultrasound (freehand) and the thickness of the malignant melanoma will be expressed in µm. Standard gold is defined as at the main objective.
Global echogenicity of the malignant melanoma in Ultrasound Biomicroscopy
Global echogenicity of the malignant melanoma in relation to the dermis: hypoechoic, isoechoic, hyperechoic
Avascular areas of malignant melanoma using power Doppler in Ultrasound Biomicroscopy
Presence of Avascular areas of malignant melanoma using power Doppler in Ultrasound Biomicroscopy Data will be compared with the histological data
Measurement of the thickness of the malignant melanoma with Ultrasound Biomicroscopy
Measurement of the thickness of malignant melanoma Ultrasound Biomicroscopy by 2 differents investigators to evaluate the intra and inter-observer matching.
Measurement of the radiofrequency signal acquired during the Ultrasound Biomicroscopy examination of malignant melanoma
The radiofrequency signal acquired in Ultrasound Biomicroscopy will be analyzed on a platform dedicated to image processing, looking for radio frequency signal specifics of melanoma, compared to adjacent healthy skin.
Structure of the malignant melanoma in Ultrasound Biomicroscopy
Homogeneous or heterogeneous structure of the malignant melanoma in Ultrasound Biomicroscopy
Hyperechoic or anechogenic foci of the malignant melanoma in Ultrasound Biomicroscopy
Presence of hyperechoic or anechogenic foci in Ultrasound Biomicroscopy
hyperechoic spans of the malignant melanomain Ultrasound Biomicroscopy
Presence of hyperechoic spans in Ultrasound Biomicroscopy
Appearance of the contours of the melanoma
Appearance of the contours of the melanoma in Ultrasound Biomicroscopy : regular, irregular, or blurred
Type of vascularization of malignant melanoma using power Doppler in Ultrasound Biomicroscopy
Type of vascularization of malignant melanoma using power Doppler in Ultrasound Biomicroscopy: homogeneous, heterogeneous Data will be compared with the histological data
Intensity of vascularization relative to the adjacent normal dermis of malignant melanoma using power Doppler in Ultrasound Biomicroscopy
Intensity of vascularization relative to the adjacent normal dermis, with Doppler parameters fixed Data will be compared with the histological data
Full Information
NCT ID
NCT04702854
First Posted
December 2, 2020
Last Updated
May 27, 2021
Sponsor
Centre Hospitalier Universitaire de Nice
1. Study Identification
Unique Protocol Identification Number
NCT04702854
Brief Title
Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma
Acronym
BMUMM
Official Title
Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
February 10, 2021 (Actual)
Primary Completion Date
December 30, 2021 (Anticipated)
Study Completion Date
December 30, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nice
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Cutaneous melanomas represent 4 to 11% of cutaneous cancers, but is responsible for 75% of the deaths reported for these pathologies. The incidence rate double every 10 years. Fourteen thousand cases and 1700 deaths were reported in France in 2015.
The local staging of the cancer is represented by the Breslow index, which is measured on histological analysis, corresponding to the maximum depth of the cancer. Breslow index is a good pronostic value, and is used to choose for the best treatment for the patient.
Having access to the Breslow index before the first resection of the tumor would allow dermatologists to make a complete resection with the best treatment, and the analysis of the sentinel lymph node, all during the same surgical time. Currently, patients need 2 surgeries : one before the Breslow index, and a second one after.
The depth of cutaneous melanoma was already evaluated with High-Frequency Ultrasound (HF-US), but gave disappointing results, with Breslow index not being accurately measured.
Only 50% of tumors less than 2mm depth were efficiently measured. Results were even worst for bigger tumors.
Ultrasound biomicroscopy (UBM) is a new approach, depending on the use of ultra high frequency and large-band transducer. Nice's CHU acquired the only ultrasound device capable of applying such ultra high frequency ultrasound (UHF-US) to human tissues. The device is a VEVO MD (Vevo MD, Toronto, Canada) and equip the Ultrasound Department since June 2018.
The images investigators can assess with this device have an axial resolution of 30µm, for a maximum emission frequency of 70MHz, which was not attainable until this day in human care.
Furthermore, when compared to some of the mono-frequency devices investigators experimented before, this device allow investigators to attain a maximum depth of analysis up to 8mm.
In consequence, this device seems to be able to realize an extremely precise analysis of the skin, and of the cutaneous melanomas, for a structural analysis, as well as a precise depth measurement, and should be evaluated in the measurement of the Breslow Index.
The objective of the study is to analyze the interest of ultrasound biomicroscopy in the pre-therapeutic evaluation of the Breslow index of cutaneous melanoma, compared to histological findings.
The study will include 60 patients with cutaneous melanomas, recently diagnosed in the Dermatology Department of the Nice University Hospital (Pr Bahadoran, Pr Passeron, Pr Lacour). Each patient will beneficiate from complete Ultrasound biomicroscopy analysis of the tumor The examination will be made blindly by 2 operator, both with experience in Ultra High frequency Ultrasound examinations (Dr Azulay, Dr Raffaelli).
The maximum depth of the melanoma (Breslow index) will be recorded in µm. After surgical resection, the histologic analysis (Dr Long, Pr Hofman, Clinical and Experimental AnatomoPathologic laboratory, Nice's University Hospital) will measure the gold-standard Breslow Index.
The comparison will analyze the capacity of Ultrasound biomicroscopy for a precise measurement of the Breslow Index, as well as the inter and intra-operator concordance.
If the results of this study are positives and suggest a modification of the therapeutic strategy, a larger multicentric study would be launched in the near future.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cutaneous Melanoma
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Experimental
Arm Type
Experimental
Arm Description
Measure of cutaneous melanomas by ultrasound biomicroscopy
Intervention Type
Diagnostic Test
Intervention Name(s)
Ultrasound Biomicroscopy
Intervention Description
Measure of cutaneous melanomas by ultrasound Biomicroscopy
Primary Outcome Measure Information:
Title
Measurement of the Breslow Index with Ultrasound Biomicroscopy
Description
The measurement of the thickness of the malignant melanoma will be carried out in Ultrasound Biomicroscopy in two orthogonal planes using the maximum value obtainedThe measurement will be performed pre-operatively with the device (transducer) attached to an articulated arm from the anterior edge of the lesion to the interface between the posterior border of the lesion and the underlying dermis or hypodermis.
The measurement will be expressed in mm. The histological measurement will be performed according to the usual techniques after fixation of the surgical specimen. It will also be expressed in µm.
Time Frame
In the 14 days following the inclusion
Secondary Outcome Measure Information:
Title
Measurement of the thickness of the malignant melanoma with High Frequency Ultrasound (18MHz) and compare it to the result obtained by Ultrasound Biomicroscopy
Description
Conventional High Frequency Ultrasound (18MHz) will be performed prior to Ultrasound Biomicroscopy analysis using an 18 MHz probe according to the usual technique used in High Frequency Ultrasound (freehand) and the thickness of the malignant melanoma will be expressed in µm. Standard gold is defined as at the main objective.
Time Frame
In the 14 days following the inclusion
Title
Measurement of the thickness of the malignant melanoma with High Frequency Ultrasound and compare it to the result obtained by Ultrasound Biomicroscopy
Description
High Frequency Ultrasound (33MHz) will be performed prior to Ultrasound Biomicroscopy analysis using an 33 MHz probe according to the usual technique used in High Frequency Ultrasound (freehand) and the thickness of the malignant melanoma will be expressed in µm. Standard gold is defined as at the main objective.
Time Frame
In the 14 days following the inclusion
Title
Global echogenicity of the malignant melanoma in Ultrasound Biomicroscopy
Description
Global echogenicity of the malignant melanoma in relation to the dermis: hypoechoic, isoechoic, hyperechoic
Time Frame
In the 14 days following the inclusion
Title
Avascular areas of malignant melanoma using power Doppler in Ultrasound Biomicroscopy
Description
Presence of Avascular areas of malignant melanoma using power Doppler in Ultrasound Biomicroscopy Data will be compared with the histological data
Time Frame
In the 14 days following the inclusion
Title
Measurement of the thickness of the malignant melanoma with Ultrasound Biomicroscopy
Description
Measurement of the thickness of malignant melanoma Ultrasound Biomicroscopy by 2 differents investigators to evaluate the intra and inter-observer matching.
Time Frame
In the 14 days following the inclusion
Title
Measurement of the radiofrequency signal acquired during the Ultrasound Biomicroscopy examination of malignant melanoma
Description
The radiofrequency signal acquired in Ultrasound Biomicroscopy will be analyzed on a platform dedicated to image processing, looking for radio frequency signal specifics of melanoma, compared to adjacent healthy skin.
Time Frame
In the 14 days following the inclusion
Title
Structure of the malignant melanoma in Ultrasound Biomicroscopy
Description
Homogeneous or heterogeneous structure of the malignant melanoma in Ultrasound Biomicroscopy
Time Frame
In the 14 days following the inclusion
Title
Hyperechoic or anechogenic foci of the malignant melanoma in Ultrasound Biomicroscopy
Description
Presence of hyperechoic or anechogenic foci in Ultrasound Biomicroscopy
Time Frame
In the 14 days following the inclusion
Title
hyperechoic spans of the malignant melanomain Ultrasound Biomicroscopy
Description
Presence of hyperechoic spans in Ultrasound Biomicroscopy
Time Frame
In the 14 days following the inclusion
Title
Appearance of the contours of the melanoma
Description
Appearance of the contours of the melanoma in Ultrasound Biomicroscopy : regular, irregular, or blurred
Time Frame
In the 14 days following the inclusion
Title
Type of vascularization of malignant melanoma using power Doppler in Ultrasound Biomicroscopy
Description
Type of vascularization of malignant melanoma using power Doppler in Ultrasound Biomicroscopy: homogeneous, heterogeneous Data will be compared with the histological data
Time Frame
In the 14 days following the inclusion
Title
Intensity of vascularization relative to the adjacent normal dermis of malignant melanoma using power Doppler in Ultrasound Biomicroscopy
Description
Intensity of vascularization relative to the adjacent normal dermis, with Doppler parameters fixed Data will be compared with the histological data
Time Frame
In the 14 days following the inclusion
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical suspicion of cutaneous melanoma
Age ≥ 18 years
Social Security affiliation
Approval of patient and signature of informed consent form
Exclusion Criteria:
Counter-indication to the surgical resection of the cutaneous melanoma
Vulnerable patient (Under-supervision patients or deprived of liberty patients)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nicolas AZULAY
Phone
04 92 03 77 16
Ext
+33
Email
azulay.n@chu-nice.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Charles RAFFAELLI
Email
raffaelli.c@chu-nice.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicolas AZULAY
Organizational Affiliation
Centre Hospitalier Universitaire de Nice
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Nice
City
Nice
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas AZULAY
Phone
04 92 03 77 16
Ext
+33
Email
azulay.n@chu-nice.fr
First Name & Middle Initial & Last Name & Degree
Nicolas AZULAY
12. IPD Sharing Statement
Learn more about this trial
Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma
We'll reach out to this number within 24 hrs